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Natural History of Very Early Onset Inflammatory Bowel Disease
in North America: A Retrospective Cohort Study
Basavaraj Kerur, MD,* Eric I. Benchimol, MD,† Karoline Fiedler, BA,‡ Marisa Stahl, MD,§ Jeffrey Hyams, MD,¶
Michael Stephens, MD,‖ Ying Lu, MD,** Marian Pfefferkorn, MD,†† Raza Alkhouri, MD,‡‡ Jennifer Strople, MD,§§
Judith Kelsen, MD,¶¶ Leah Siebold, MD,‖‖ Alka Goyal, MD,***, Joel R. Rosh, MD,††† Neal LeLeiko, MD, PhD,‡‡‡
Johan Van Limbergen, MD,§§§ Anthony L. Guerrerio, MD, PhD,¶¶¶ Ross Maltz, MD,‖‖‖ Lina Karam, MD,**** Eileen
Crowley, MD,§§§§§ Anne Griffiths, MD,‡ Melvin B. Heyman, MD, MPH,†††† Mark Deneau, MD,‡‡‡‡ Keith Benkov,
MD,§§§§ Joshua Noe, MD,¶¶¶¶ Dedrick Mouton, MD,‖‖‖‖ Helen Pappa, MD,***** Joseph A. Galanko, PhD,††††† Scott
Snapper, MD, PhD,‡‡‡‡‡ Aleixo M. Muise, MD, PhD,‡ and Michael D. Kappelman, MD, MPH†††††
Background: The incidence of very early onset inflammatory bowel disease (VEOIBD) is increasing, yet the phenotype and natural history of
VEOIBD are not well described.

Methods: We performed a retrospective cohort study of patients diagnosed with VEOIBD (6 years of age and younger) between 2008 and 2013
at 25 North American centers. Eligible patients at each center were randomly selected for chart review. We abstracted data at diagnosis and at 1, 3,
and 5 years after diagnosis. We compared the clinical features and outcomes with VEOIBD diagnosed younger than 3 years of age with children
diagnosed with VEOIBD at age 3 to 6 years.
Results: The study population included 269 children (105 [39%] Crohn’s disease, 106 [39%] ulcerative colitis, and 58 [22%] IBD unclassified). The

median age of diagnosis was 4.2 years (interquartile range 2.9–5.2). Most (94%) Crohn’s disease patients had inflammatory disease behavior (B1).
Isolated colitis (L2) was the most common disease location (70% of children diagnosed younger than 3 years vs 43% of children diagnosed 3 years
and older; P = 0.10). By the end of follow-up, stricturing/penetrating occurred in 7 (6.6%) children. The risk of any bowel surgery in Crohn’s disease was 3% by 1 year, 12% by 3 years, and 15% by 5 years and did not differ by age at diagnosis. Most ulcerative colitis patients had pancolitis
(57% of children diagnosed younger than 3 years vs 45% of children diagnosed 3 years and older; P = 0.18). The risk of colectomy in ulcerative
colitis/IBD unclassified was 0% by 1 year, 3% by 3 years, and 14% by 5 years and did not differ by age of diagnosis.

Conclusions: Very early onset inflammatory bowel disease has a distinct phenotype with predominantly colonic involvement and infrequent
stricturing/penetrating disease. The cumulative risk of bowel surgery in children with VEOIBD was approximately 14%–15% by 5 years. These
data can be used to provide anticipatory guidance in this emerging patient population.
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BACKGROUND
Inflammatory bowel disease (IBD) has emerged as a global
disease with a rising prevalence in every continent.1 Many patients
are diagnosed early in life; between 5% and 25% of IBD cases develop under the age of 18 years.2 Pediatric IBD is further classified
as early onset IBD (onset under age 10) and very early onset IBD
(VEOIBD) defined as onset under 6 years of age.3, 4 Historically,
VEOIBD was thought to comprise approximately 15% of pediatric patients with IBD.5 However, emerging data suggest that the
incidence of VEOIBD is increasing.6, 7
Genetic factors are considered to play a more important
role in the pathogenesis of VEOIBD and most specifically those
patients with disease onset during the first year of life. Several
genetic mutations specific to VEOIBD such as IL-10RA,
IL10-RB, IL-10, XIAP, ADAM17, EPCAM, FOXP3, LRBA,
SKIV2L, TTC37, NCF2/RAC2, and NCF4 have been recently
identified.3, 4, 8, 9 Given the genetic differences in VEOIBD compared with later onset IBD, it is possible that the phenotype,
clinical course, and response to treatment may also differ.
With the increasing incidence of VEOIBD, natural history studies of this emerging condition are needed to (1) better
understand prognosis, (2) provide anticipatory guidance to patients/families, and (3) risk stratify patients to guide diagnostic
and therapeutic decisions (ie, precision medicine). Although
many gastroenterologists believe that patients with VEOIBD
have a poor prognosis and low response rates to conventional
treatment,10 the natural history of VEOIBD has not been well
established.11 To date, there is a paucity of large cohort studies
of representative patient populations, and existing reports have
been contradictory. For example, though several studies have
suggested that VEOIBD has an aggressive phenotype with poor
outcomes and increased frequency of surgery and other complications,9, 10, 12, 13 more recent studies have shown that risk of
surgery in VEOIBD is similar to older onset of pediatric IBD.13,
14
In fact, a few studies have even suggested the risk of surgery
in VEOIBD is less than that of older children,7, 15 and another
study indicated that children with VEOIBD are more likely to
have mild disease at diagnosis.16
We therefore undertook a large multicenter study across
North America to describe the clinical and phenotypic characteristics of VEOIBD at presentation. We also characterized the
natural history of VEOIBD including diagnostic reclassification, evolution in disease behavior, and risk of surgery.

METHODS
Overall Study Design
We conducted a retrospective cohort study of patients
diagnosed with VEOIBD (6 years of age and younger) between 2008 and 2013 at 25 North America centers participating
in the Crohn’s & Colitis Foundation’s Pediatric Resource
Organization for Kids with Inflammatory Intestinal Digestive
Diseases (PRO-KIIDS) network.17
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Study Population
Inclusion criteria included (1) meeting standardized diagnostic criteria based on endoscopic, histologic, and radiographic evidence of IBD; 18 (2) younger than 6 years of age at
the time of diagnosis; and (3) date of diagnosis between 2008
and 2013. Patients with another diagnosis that could account
for an IBD-like presentation such as cow’s milk protein allergy
(CMPA), juvenile polyps, and microscopic colitis were excluded. As per standard of care at the time, patients were not
required to undergo genetic testing for mutations associated
with VEOIBD.
To minimize the possibility of selection bias, we selected
PROKIIDS sites based on their ability to identify and obtain
records for all cases of VEOIBD diagnosed at their practices
(ie, complete case ascertainment). To avoid referral bias, we included only patients who were diagnosed at participating centers. At each site, all potentially eligible patients were identified.
A central biostatistician randomly ordered the list of potentially eligible patients, and sites sequentially reviewed charts to
determine final eligibility. Our goal was to review 10 charts at
each site. Not all centers identified 10 eligible patients. A few
centers elected to review additional participants.

Data Collection
A trained pediatric gastroenterologist with expertise in
IBD reviewed medical records and abstracted data related to
patient demographics, clinical course, and treatment utilization using a standardized case reporting form. All physicians
and study staff received training on standardized data definitions, and any questions or ambiguities identified during chart
review were addressed by the study team and disseminated to
all centers by the Data Coordinating Center. For each patient,
data were abstracted at the after time points when available: diagnosis, 1 year after diagnosis, 3 years after diagnosis, 5 years
after diagnosis, and at most recent site visit. All study data were
entered electronically using REDCap data capture tools hosted
at SickKids Research Institute in Toronto.19

Definitions
We defined the date of diagnosis as the date of first endoscopy. We defined initial IBD diagnosis as the original classification of Crohn’s disease (CD), ulcerative colitis (UC), or IBD
unclassified (IBD-U) at diagnosis (or within the first 3 months).
We defined final diagnosis as the most recent classification on
final site visit. We described disease extent and behavior using
Paris classification.20

Statistical Analysis
The final study sample included all patients whose abstracted records included a date of birth and complete disease
classification at the time of diagnosis. We used standard descriptive and univariate statistics to characterize our overall

Clinical Features and Outcomes of VEOIBD
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study population and specific subgroups of interest, including
reporting of medians (and interquartile range [IQR]) and proportions. The × 2 or Fisher exact tests were used to compare age
groups at diagnosis (3 years and older or younger than 3 years
of age) on the basis of clinical and phenotypic characteristics,
disease location, type, extent, and disease behavior. KaplanMeier survival curves were used to compare time to surgical
event by age group. P values less than 0.05 were considered
statistically significant. All analyses were conducted using SAS
Version 9.4 (SAS Institute, Cary, NC).

Ethical Considerations
Institutional review board approval was obtained at all
participating centers before patient identification and data
collection.

RESULTS
The study population included 269 children with
VEOIBD across 25 North American centers (see appendix).
The median age at diagnosis was 4.2 years (range 0.4–6 y). The
characteristics of the study population are displayed in Table 1.
A total of 71 (26%) were diagnosed under age 3. The study
population was predominantly white (63%), 8% were Jewish,
and 7% were Hispanic. Only 5 children (1.7%) had a diagnosed
coexisting immunological disorder.

Initial Presentation
Of the 71 patients diagnosed younger than 3 years of
age, 26 (37%) had CD, 23 (32%) had UC, and 22 (31%) IBDU. Of the 198 patients diagnosed between 3 and 6 years of
age, 79 (40%) had CD, 83 (42%) had UC, and 36 (18%) had
IBD-U (Table 2). In both age groups, the 2 most common
symptoms at diagnosis were bloody diarrhea (88%) and abdominal pain (50%). The frequency of these symptoms did
not differ between CD, UC, and IBD-U (data not shown).
The incidence of any extraintestinal manifestations (EIMs)
among Crohn’s, UC, and IBD-U was 32%, 8%, and 11%, respectively (P < 0.0001). The occurrence of EIMs was similar
in both age groups.
Of the 71 patients diagnosed under 3 years, 8 patients
(11%) had a family history of IBD compared with 29 of 198 patients (15%) diagnosed at 3 years and older (P = 0.55). We noted
consanguinity in <1% of parents of children with VEOIBD.
Over 94% of CD patients in both age groups had inflammatory behavior (B1) at diagnosis (Table 3). The most common
disease locations at diagnosis were colonic (L2) and ileocolonic
(L3) in both age groups. In children diagnosed under age 3,
the proportion with L2 and L3 disease were 70% and 15%, respectively. In children diagnosed between 3 and 6 years of age,
the proportion with L2 and L 3 disease were 43% and 29%,
respectively. Five subjects (19%) diagnosed under age 3 and 29
subjects (37%) diagnosed over age 3 had upper tract disease;

TABLE 1. Demographics of Children with VEOIBD
Demographics of VEOIBD (N = 269)
Age at diagnosis
Median (range)
25th, 75th percentile
Age (years)
0–3
3–6
Sex
Male
Female
Race
White
African American
Asian
Amer Indian/Alaska Nat
Other Pacific Islander
Mixed
Unknown
Country of Origin
USA
Canada
Other
Unknown
Ethnicity
Jewish
  Yes
  No
  Mixed
  Unknown
Hispanic
  Yes
  No
  Mixed
  Unknown
Coexisting immune disorder
CGD
IL-10/R receptor def
IPEX
NEMO
WAS
X- Agammaglobinemia
Other*

N (%)
4.2 (0.4, 6.0)
(2.9, 5.2)
71 (26)
198 (74)
141 (54)
119 (46)
170 (63)
10 (4)
12 (4)
0 (0)
0 (0)
7 (3)
70 (26)
41 (15)
189 (70)
5 (2)
34 (13)

21 (8)
106 (39)
1 (0.4)
141 (52)
18 (7)
142 (53)
4 (1)
105 (39)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1 (0.4)
4 (1.5)

*The four “others” are Down Syndrome, Epidermolysis Bullosa, NK cell defect and
STXBP2 Mutation, and NK cell deficiency.

only 2 patients had isolated upper tract disease. Perianal disease
was present at diagnosis in 12% of children under age 3 and
20% in children older than 3 years. In total, 62 of 105 children
(50%) with CD had granulomas on pathology.
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TABLE 2. Clinical Characteristics of IBD at Diagnosis Based on Age at Diagnosis
Age at Diagnosis
Clinical characteristics at diagnosis
IBD type
Crohn’s disease
Ulcerative colitis
IBD- Unclassified
GI symptoms
Diarrhea
Blood per rectum
Abdominal pain
Vomiting
Decrease appetite
Weight loss
Extraintestinal manifestation
Erythema Nodosum
Pyoderma gangrenosum
Arthritis
Arthralgia
Oral ulcers
Folliculitis
Chronic fevers
Recurrent infections
Family history of IBD 1st degree
Surgery <3 months of diagnosis

0–3 yrs (n = 71)
n (%)

3–6 yrs (n = 198)
n (%)

26 (37)
23 (32)
22 (31)

79 (40)
83 (42)
36 (18)

0.08

65 (88)
66 (93)
30 (48)
9 (13)
22 (37)
28(39)

171 (88)
165 (84)
132 (70)
22 (12)
54 (32)
66(33)

1.0
0.07
0.003
0.68
0.53

0 (0)
0 (0)
1 (1)
2 (3)
2 (3)
0 (0)
1 (1)
4 (6)
8 (11)
3 (4)

3 (2)
0 (0)
6 (3)
15 (8)
6 (3)
2 (1)
23 (12)
7 (4)
29 (15)
3 (2)

0.37
—
0.68
0.16
1.0
1.0
0.007
0.50
0.55
0.19

In patients with UC, the most common disease location
was E3 (extensive hepatic flex) and E4 (pancolitis) in both age
groups. Isolated proctitis (E1) was rare (Table 3). Terminal ileal
involvement was found in 5% of IBD-U cases diagnosed younger
than 3 years of age and in 14% diagnosed between ages 3 and 6.

Treatments
The various treatments and medications used during
the first year after diagnosis are reported in Table 4. Exclusive
enteral nutrition (EEN) was used in 10 children (4%). A total
of 143 children (55%) had more than 1 course of steroids
during the first year of diagnosis, each course lasting 4 to
8 weeks. Additionally, 5-aminosalicylates were used in 191
children (73%), and 112 children (43%) were exposed to
immunomodulators (6MP/azathioprine/methotrexate). Four
patients were started on tacrolimus and 2 on cyclosporine.
A total of 46 (18%) had exposure to biologics during the first
year after diagnosis.
Over the course of 5 years of follow-up, cumulative use
of immunomodulators and biologics was 60% and 41%, respectively (Table 4). The rate and time to initiation of biologics was
not different in patients with CD, UC, or IBD-U or by age at
diagnosis (Fig. 1A, B).
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P value

Natural History and Outcomes
During follow-up, the diagnosis changed from UC/
IBD-U to Crohn’s disease in 19 of 164 (11.5%) children. In children younger than 3 years of age, 8 of 45 patients (18%) were
reclassified compared with 11 of 119 patients (9%) of the older
group (P = 0.17). In children initially diagnosed with CD, 1
child (4%) diagnosed at younger than 3 years of age progressed
from B1 to B2/B3 by 5 years. In children diagnosed with CD at
3 to 6 years of age, 4 children (5%) progressed from B1 toB2/
B3 behavior.
In CD, the overall risk of bowel-related surgery was 3%
by 1 year, 12% by 3 years, and 15% by 5 years. The risk of bowel
surgery and time to surgery was not different by age at diagnosis
(Fig. 2A). Colectomy risk in UC/IBD-U was 0% by 1 year, 3%
by 3 years, and 14% by 5 years, without significant difference by
age of diagnosis (Fig. 2B).

DISCUSSION
High quality studies evaluating the clinical characteristics
and natural history of VEOIBD in large generalizable samples
are lacking. We present findings from a large, multicenter, geographically diverse cohort of VEOIBD patients. Compared
with the previously described epidemiological and clinical

Clinical Features and Outcomes of VEOIBD
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TABLE 3. Disease Location and Behavior of IBD Phenotype at Diagnosis
Age at Diagnosis
Paris Classification

0–3 yrs (n = 71)
n (%)

3–6 yrs (n = 198)
n (%)

(N = 26)
0 (0%)
18 (70%)
4 (15%)
0 (0%)
3 (11%)
1 (4%)

(N = 79)
6 (7%)
34 (43%)
23 (29%)
2 (3%)
10(13%)
4 (5%)

5 (19%)
19 (73%)
2 (8%)
(N = 26)
25 (96)
0 (0)
0 (0)
0 (0)
1 (4)

29 (37%)
45 (57%)
5 (6%)
(N = 79)
74 (94)
0 (0)
2 (3)
0 (0)
3 (4)

3 (12)
22 (85)
1 (4)
(N = 23)
0 (0%)
2 (9%)
1 (4%)
13 (57%)
2 (9%)
4 (17%)
1 (4%)
(N = 22)
4 (18)
1 (5)
4 (18)
4 (18)
4 (18)
3 (14)
21 (95)

16 (20)
61 (77)
2 (3)
(N = 83)
3 (4%)
13 (16%)
21 (25%)
37 (45%)
6 (7%)
2 (2%)
1(1%)
(N = 36)
9 (25)
5 (14)
3 (8)
7 (19)
4 (11)
4 (11)
33 (92)

CD disease location (Paris) (n = 105)
L1
L2
L3
  Isolated L4
   Micro disease only
  Unknown
L4
  Yes
  No
  Unknown
CD disease behavior (n = 105)
B1
B2 Only
B3 Only
Both B2 and B3
Unknown
Perianal disease
Yes
No
Unknown
UC disease location (n = 106)
E1 (Proctitis)
E2 (Left sided)
E3 (extensive hepatic flex)
E4 (pancolitis)
Not Assessed (complete colonoscopy not performed)
Microscopic disease only
Unknown
IBD-U Location (endoscopic) (n = 58)b
Proximal Bowel
Distal Ileum
Cecum
Ascending Colon
Transverse Colon
Descending Colon
Recto-Sigmoid

P value
0.1a

0.14a

0.58a

0.39a

0.18a

“Unknown” and “Microscopic disease only” are not included in the P value computations.
Disease location indicate the region involved but are not mutually exclusive

a

b

characteristics of IBD presenting in older children, our findings suggest that VEOIBD is composed of a distinct clinical
phenotype but may not necessarily have a more aggressive disease course. Key findings include the following: (1) disease
classification at diagnosis is primarily UC or IBD-U, likely due
to colitis-predominant disease, (2) diagnostic reclassification to

CD is common, (3) internal penetrating/stricturing disease is
uncommon, (4) antitumor necrosis factor (anti-TNF) biologics
are widely used, including off-label use in patients younger than
6 years of age, and (5) other clinical features and the natural
history of VEOIBD seem to be similar to later onset pediatric
IBD. Overall, we observed no substantial differences in the
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TABLE 4. Exposure to IBD Medications
1st year of diagnosis
N (%)

5 th year of diagnosis
N (%)

Corticosteroids (>1 course ~4–8 wks)
Oral Enteric (Budesonide)
Oral systemic
IV systemic
Rectal
Biologics
Infliximab/Adalimumab
Other
Immunomodulators
Azathioprine/6-Mercaptopurine
Tacrolimus
Cyclosporine
Methotrexate (IM or oral)
ASA
Sulfasalazine
Mesalamine
Olsalazine
Exclusive Enteral Nutrition (EEN)

143 (55)
5 (2)
132 (51)
23 (9)
18 (7)
46 (18)
44 (17)
2 (1)
112 (43)
96 (37)
4 (2)
2 (1)
17 (7)
191 (73)
90 (34)
111 (43)
1 (0.4)
10 (4)

174 (67)
21 (8)
166 (64)
53 (20)
30 (11)
107 (41)
105 (40)
2 (1)
157 (60)
128 (49)
5 (2)
2 (1)
57 (22)
208 (80)
104 (40)
137 (52)
1 (0.4)
18 (7)

phenotype or natural history of children diagnosed under the
age of 3 years compared with children diagnosed between 3 and
6 years of age.
The most common presenting symptoms of VEOIBD
observed in our study were chronic diarrhea, bleeding per
rectum, and abdominal pain. This was similar to prior published studies.13, 15, 16 We observed extraintestinal manifestations
in 14% of the children diagnosed with VEOIBD at a younger
age (younger than 3 y) and in 33% of those diagnosed between
3 and 6 years old, though this difference was not statistically
significant. These findings reinforce prior work showing no differences in the prevalence of extraintestinal manifestations in
VEOIBD compared with older onset children.10
Similar to previously published studies,5, 12, 13, 15, 21, 22 the
most common classification of VEOIBD at diagnosis in our
study was UC and IBD-U in more than 60% of patients in both
age groups. This is likely a result of the most frequent anatomic
location of inflammation being the colon. In children with CD,
the most common disease location was colonic (L2), followed
by ileocolonic (L3) disease. Isolated ileal disease, more common
in adults and older children with CD,23 was rare in our cohort.
We observed no isolated ileal cases in children under age 3 at
diagnosis and only 6 (7%) in children 3 to 6 years of age at
diagnosis. In children with UC, pancolitis (E4) was the most
common disease location in both age groups. Isolated proctitis
was rare, which is consistent with other published studies.13
Several prior studies have reported that perianal disease
is common in VEOIBD, with mutations affecting IL-10 or

IL-10 receptor signaling.24–26 Perianal disease was seen in 34%
of VEOIBD from a single-center study.12 In our study, the presence of perianal disease was less common, seen in only 12% of
children diagnosed at younger than 3 years of age and 20% of
children between 3 and 6 years of age. Our findings are consistent with those observed in a more recent multicenter study,13
suggesting probable referral bias in earlier single-center series.
We observed relatively high anti-TNF use in our cohort. A total of 122 (42%) children were exposed anti-TNF by
5 years from diagnosis. Though infliximab and adalimumab are
only FDA approved in patients older than 6 years of age, 46
children in our cohort were younger than 6 years at the time
of first exposure to biologics. We observed no differences in exposure to biologics in those diagnosed younger than 3 years as
compared with children diagnosed at 3 to 6 years old.
We noted a change in diagnosis from UC/IBD-U to
Crohn’s disease in 19 of 164 (11.5%) of children during follow-up.
However, a significant proportion of children with VEOIBD continued to be classified as IBD-U after 5 years of follow-up, suggesting difficulty with making a definitive classification.7, 13, 16
Traditionally, VEOIBD has been considered to be a more
aggressive phenotype with disease progression.12 In our cohort,
the observed risk of bowel surgery in CD was 3% at 1 year, 12%
at 3 years, and 15% at 5 years. Thus, the observed risk of surgery
in this VEOIBD cohort is similar to that of children diagnosed
with CD at an older age.14 This finding is consistent with another
recent study from Canada showing that the risk of surgery and
use of hospital resources were lower in VEOIBD compared with
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FIGURE 1. A, Biologics free survival in CD. B, Biologics free survival in in
UC & IBD-U; x axis, years since diagnosis; y axis, biologics free survival;
blue line, diagnosed younger than 3 years old; red line, diagnosed
3 years and older.

those with older onset pediatric IBD.7 We observed the risk of
colectomy in UC/IBD-U to be 0% by 1 year, 3% by 3 years, and
14% by 5 years. Prior literature regarding the risk of colectomy in
VEOIBD is conflicting. One study demonstrated a higher risk of
colectomy in young children10; however, a more recent Canadian
study showed similar colectomy risk in children diagnosed with
VEOIBD vs those with onset later in childhood.7
This study is one of the largest cohorts of VEOIBD
looking at clinical features in the first 5 years from diagnosis.
Other strengths include the large number and geographic diversity of participating centers. We undertook great efforts to minimize recall bias by selecting centers who could identify their
complete population of VEOIBD patients and then randomly
select participants for chart review. Additionally, we sought to
minimize referral bias by excluding patients seen for second
opinions after diagnosis. Thus, we believe our sample to approximate a “real world” cohort with robust generalizability.
There were several limitations of the study. As with many
retrospective studies, missing data can be an issue. In our study,
anthropometric data were not available for 50% of children,
and other clinical details and/or dates could not always be ascertained during chart review. Additionally, our sample was
predominantly white. Little is known about the distribution of
IBD, particularly VEOIBD, among persons of different races
and ethnicities. Thus, we cannot evaluate the extent to which

Clinical Features and Outcomes of VEOIBD

FIGURE 2. A, Surgery free survival (Bowel surgery in Crohn’s disease).
B, Colectomy free survival (UC & IBD-U); x axis, years since diagnosis; y
axis, risk of bowel surgery; blue line, diagnosed younger than 3 years
old; red line, diagnosed 3 years and older.

our study population is adequately representative of non-European populations. Although we acknowledge that our study
centers were largely academic medical centers that potentially
could introduce referral bias, we attempted to mitigate this by
excluding patients diagnosed at other centers as described previously. Finally, as our cohort had only 9 patients with VEOIBD
diagnosed under the age of 1 year old, we could not characterize the clinical course of infantile-onset IBD. Additionally,
the majority of patients in this cohort did not undergo genetic
testing to describe monogenic disorders in VEOIBD
In summary, our study highlights that VEOIBD patients
have a distinct phenotype. In contrast to later onset pediatric
IBD, a greater proportion of patients in this VEOIBD cohort
were classified as UC/IBD-U, had primarily colonic disease,
and infrequently progressed to stricturing/internal penetrating
complications. The requirement for surgery seems to be no
more aggressive than that of later onset pediatric IBD. The results of this study can be used to counsel families of VEOIBD
patients and highlight the need for clinical and comparative effectiveness and safety research in this emerging clinical population. In particular, considering the increasing off-label use of
anti-TNF biologics in this patient population, there is a great
need for effectiveness and safety research of these medications
in VEOIBD.
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Appendix 1. Site List for VEOIBD Study
Study Site
01_Chapel Hill UNC
02_Toronto SickKids
03_Boston
04_Chicago Lurie
05_StLouis CardGlennon
06_Philadelphia CHOP
07_Ottawa CHEO
08_Pittsburgh
09_NewYork Cohen
10_Connecticut
11_Morristown GoryebAHS
12_Providence Hasbro
13_NewYork MtSinai
14_Halifax IWK
15_Baltimore JHMI
16_Rochester Mayo
17_Milwaukee MCW
18_Nashville MonroeCarell
19_Columbus Nationwide
20_Carmel Riley
21_Houston TCH
22_Buffalo
23_SanFrancisco UCSF
24_SaltLakeCity_Utah
25_KansasCity_Mercy
26 Missing

Frequency

Percent

9
8
6
10
5
10
21
10
13
16
10
10
10
10
11
16
9
10
10
9
9
11
10
8
9
9

3.85
3.08
3.46
3.85
1.92
3.85
8.08
3.85
5.00
6.15
3.85
3.85
3.85
3.85
4.23
6.15
3.46
3.85
3.85
3.46
3.46
4.23
3.85
3.08
3.46

